Vijaya Diagnostic Centre (VIJAYA) Q4 20/21 earnings summary

Executive summary

• FY21 consolidated revenue grew 11% YoY to Rs. 37,674.57 lakhs and PAT rose 36% to Rs. 8,512.65 lakhs, despite COVID-19 disruption.

• Standalone revenue increased 12% to Rs. 36,731.59 lakhs; standalone PAT grew 35% to Rs. 8,282.15 lakhs.

• Priorities remained volume growth, stronger brand differentiation and cost optimization to support consistent margin growth.

Financial highlights

• Consolidated PBT was Rs. 11,212.39 lakhs versus Rs. 8,342.72 lakhs in FY20; PAT was Rs. 8,512.65 lakhs versus Rs. 6,277.61 lakhs.

• Consolidated revenue from operations was Rs. 37,674.57 lakhs versus Rs. 33,882.09 lakhs; other income was Rs. 1,184.64 lakhs versus Rs. 1,536.14 lakhs.

• Standalone PBT was Rs. 10,958.62 lakhs versus Rs. 8,175.05 lakhs; PAT was Rs. 8,282.15 lakhs versus Rs. 6,123.80 lakhs.

• Consolidated operating cash flow was Rs. 12,963.59 lakhs versus Rs. 10,611.02 lakhs; capex and CWIP purchases used Rs. 3,213.01 lakhs.

• FY20 consolidated other income included Rs. 182.15 lakhs profit on slump sale; FY21 had no comparable slump-sale gain.

Outlook and guidance

• Strategy emphasized volume growth, brand differentiation and an optimized cost structure to deliver consistent margin growth.

• Based on estimates available at the reporting date, full recovery of asset carrying amounts was expected, with no material adverse operational impact foreseen; pandemic developments remained under review.